Seagen, Astellas' Padcev snares full approval and expands into second-line treatment on path to blockbuster land

That didn't take long: Shortly after Seagen and Astellas Pharma's Padcev nabbed a priority review for two bladder cancer applications, the FDA has returned with double green lights—and it's given the OK more than a month ahead of schedule.